Synthesis and Biological Evaluation of S-, O- and Se-Containing Dispirooxindoles

Synthesis and Biological Evaluation of S-, O- and Se-Containing Dispirooxindoles

A series of novel S-, O- and Se-containing dispirooxindole derivatives has been synthesized using 1,3-dipolar cycloaddition reaction of azomethine ylide generated from isatines and sarcosine at the double C=C bond of 5-indolidene-2-chalcogen-imidazolones (chalcogen was oxygen, sulfur or selenium). T...

Full description

Bibliographic Details
Main Authors:	Maksim Kukushkin, Vladimir Novotortsev, Vadim Filatov, Yan Ivanenkov, Dmitry Skvortsov, Mark Veselov, Radik Shafikov, Anna Moiseeva, Nikolay Zyk, Alexander Majouga, Elena Beloglazkina
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Molecules
Subjects:	dispirooxindoles anticancer activity cytotoxicity 3D molecular docking p53/MDM2 interaction
Online Access:	https://www.mdpi.com/1420-3049/26/24/7645

Similar Items

Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction
by: Anastasia Beloglazkina, et al.
Published: (2020-03-01)

Synthesis and Biological Evaluation of Novel <i>Dispiro</i>-Indolinones with Anticancer Activity
by: Yan A. Ivanenkov, et al.
Published: (2023-01-01)

A Facile Synthesis of Functionalized Dispirooxindole Derivatives via a Three-Component 1,3-Dipolar Cycloaddition Reaction
by: Liang Ouyang, et al.
Published: (2013-05-01)

An Efficient Synthesis of Novel Dispirooxindole Derivatives via One-Pot Three-Component 1,3-Dipolar Cycloaddition Reactions
by: Yucheng Wang, et al.
Published: (2012-10-01)

Dispirooxindoles Based on 2-Selenoxo-Imidazolidin-4-Ones: Synthesis, Cytotoxicity and ROS Generation Ability
by: Vladimir K. Novotortsev, et al.
Published: (2021-03-01)

Identification of new inhibitors of Mdm2–p53 interaction via pharmacophore and structure-based virtual screening
by: Atatreh N, et al.
Published: (2018-11-01)

Dispirooxindole-β-Lactams: Synthesis via Staudinger Ketene-Imine Cycloaddition and Biological Evaluation
by: Vadim E. Filatov, et al.
Published: (2022-06-01)

Diastereoselective Synthesis of Dispiro[Imidazothiazolotriazine-Pyrrolidin-Oxindoles] and Their Isomerization Pathways in Basic Medium
by: Alexei N. Izmest′ev, et al.
Published: (2023-11-01)

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans
by: Venkatesh, Byrappa, et al.
Published: (2016)

Synthesis, Structure and Stereochemistry of Dispirocompounds Based on Imidazothiazolotriazine and Pyrrolidineoxindole
by: Alexei N. Izmest’ev, et al.
Published: (2022-11-01)

Synthesis of some quinazolinones inspired from the natural alkaloid L-norephedrine as EGFR inhibitors and radiosensitizers
by: Mostafa M. Ghorab, et al.
Published: (2021-01-01)

Immunohistochemical detection of P53 and Mdm2 in vitiligo
by: Ola A Bakry, et al.
Published: (2012-01-01)

Methoxyphenyl Imidazolines as Potential Activators of p53
by: Daniil R. Bazanov, et al.
Published: (2022-11-01)

p53 biology and reactivation for improved therapy in MDS and AML
by: Joanna E. Zawacka
Published: (2024-03-01)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
by: Zuzana Mrkvová, et al.
Published: (2019-06-01)

Role of Sex in the Therapeutic Targeting of p53 Circuitry
by: Francesca Mancini, et al.
Published: (2021-07-01)

Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells
by: Habibullah MM, et al.
Published: (2022-06-01)

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
by: Hui Qin Wang, et al.
Published: (2017-04-01)

Evolution of the p53-MDM2 pathway
by: Emma Åberg, et al.
Published: (2017-08-01)

Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents
by: Agostinho Lemos, et al.
Published: (2019-05-01)

Investigation of the In-Vivo Cytotoxicity and the In Silico-Prediction of MDM2-p53 Inhibitor Potential of <i>Euphorbia peplus</i> Methanolic Extract in Rats
by: Yasmina M. Abd-Elhakim, et al.
Published: (2019-11-01)

Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis
by: Xiufang Xiong, et al.
Published: (2014-08-01)

Synthesis, Cytotoxicity Evaluation and Molecular Docking Studyof <i>N</i>-Phenylpyrazoline Derivatives
by: Artania Adnin Tri Suma, et al.
Published: (2019-08-01)

p53 and MDM2 protein expression in actinic cheilitis
by: Maria da Conceição Andrade de Freitas, et al.
Published: (2008-12-01)

Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53
by: Xin Tian, et al.
Published: (2016-10-01)

p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant
by: Timothy J. Humpton, et al.
Published: (2018-12-01)

miR-1305 Inhibits The Progression Of Non-Small Cell Lung Cancer By Regulating MDM2
by: Cai Y, et al.
Published: (2019-11-01)

Preclinical In Vitro Investigation of MDM2 Inhibition in Combination with Antiangiogenic Therapy for Breast Cancer Treatment
by: Ali M. Alaseem, et al.
Published: (2023-02-01)

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
by: Javier Octavio Mejía-Hernández, et al.
Published: (2022-08-01)

Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
by: Yamamoto N, et al.
Published: (2024-03-01)

Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens
by: Ali M. Alaseem
Published: (2023-10-01)

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
by: Lucia Haronikova, et al.
Published: (2021-12-01)

Structure based virtual screening, docking and molecular dynamic simulation studies to identify potent mdm2-p53 inhibitors: Future implications for cancer therapy
by: B Vijay Raj, et al.
Published: (2017-01-01)

Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX
by: Yali Wang, et al.
Published: (2022-06-01)

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
by: Yuan Fang, et al.
Published: (2020-07-01)

Chemical Variations on the p53 Reactivation Theme
by: Carlos J. A. Ribeiro, et al.
Published: (2016-05-01)

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53
by: Zhaofeng Liu, et al.
Published: (2024-02-01)

RBM10, a New Regulator of p53
by: Ji Hoon Jung, et al.
Published: (2020-09-01)

Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
by: Marwan Kwok, et al.
Published: (2021-09-01)

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death
by: Nayeong Koo, et al.
Published: (2022-04-01)